<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369016</url>
  </required_header>
  <id_info>
    <org_study_id>17322</org_study_id>
    <secondary_id>2014-000925-19</secondary_id>
    <nct_id>NCT02369016</nct_id>
  </id_info>
  <brief_title>Phase III Copanlisib in Rituximab-refractory iNHL</brief_title>
  <acronym>CHRONOS-2</acronym>
  <official_title>A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety of copanlisib
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 22, 2015</start_date>
  <completion_date type="Anticipated">December 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 7, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-emergent adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with serious adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal lab parameters</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with abnormal vital signs</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>Copanlisib (BAY 80-6946)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with rituximab-refractory iNHL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copanlisib (BAY 80-6946)</intervention_name>
    <description>60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle</description>
    <arm_group_label>Copanlisib (BAY 80-6946)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of indolent B-cell NHL, with histological subtype
             limited to the following:

               -  Follicular lymphoma (FL) grade 1-2-3a.

               -  Small lymphocytic lymphoma (SLL) with absolute lymphocyte count &lt; 5 x 10*9/L at
                  the time of diagnosis and at study entry.

               -  Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM).

               -  Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal).

          -  Patients must have received two or more prior lines of treatment. A previous regimen
             is defined as one of the following: at least two months of single-agent therapy, at
             least two consecutive cycles of polychemotherapy, autologous transplant,
             radioimmunotherapy.

          -  Prior therapy must include rituximab and alkylating agents.Prior exposure to
             idelalisib or other PI3K inhibitors is acceptable (except to copanlisib) provided that
             there is no resistance.

          -  Patients must be refractory to the last rituximab-based treatment, defined as no
             response or response lasting &lt; 6 months after completion of treatment. Time interval
             to assess refractoriness will be calculated between the end date (last day) of the
             last rituximab-containing regimen and the day of diagnosis confirmation of the
             subsequent relapse.

          -  Patients must have at least one bi-dimensionally measurable lesion (which has not been
             previously irradiated) according to the Recommendations for Initial Evaluation,
             Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano
             Classification.

          -  Patients affected by WM, who do not have at least one bi-dimensionally measurable
             lesion in the baseline radiologic assessment, must have measurable disease, defined as
             presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ≥ 2 x upper
             limit of normal (ULN)and positive immunofixation test.

          -  ECOG performance status ≤ 1

          -  Adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  Histologically confirmed diagnosis of FL grade 3b.

          -  Chronic lymphocytic leukemia (CLL).

          -  Transformed disease (assessed by investigator):

               -  histological confirmation of transformation, or

               -  clinical and laboratory signs: rapid disease progression, high standardized
                  uptake value (SUV) (&gt; 12) by positron emission tomography (PET) at baseline if
                  PET scans are performed (optional).

          -  Bulky disease - Lymph nodes or tumor mass (except spleen) &gt;= 7cm LD (longest diameter)

          -  Known lymphomatous involvement of the central nervous system.

          -  Uncontrolled arterial hypertension despite optimal medical management (per
             investigator's assessment).

          -  Type I or II diabetes mellitus with HbA1c &gt; 8.5% at Screening.

          -  Known history of human immunodeficiency virus (HIV) infection.

          -  Active clinically serious infections &gt; CTCAE Grade 2

          -  Active Hepatitis B or hepatitis C

          -  History or concurrent condition of interstitial lung disease of any severity and/or
             severely impaired lung function (as judged by the investigator)

          -  History of having received an allogeneic bone marrow or organ transplant

          -  Positive cytomegalovirus (CMV) PCR test at baseline

          -  Pregnant or breast-feeding patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lesnoy</city>
        <zip>223040</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaú</city>
        <state>Sao Paulo</state>
        <zip>17210-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>France</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeollabuk-do</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeollanam-do</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almada</city>
        <zip>2801-951</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penza</city>
        <zip>440071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Taiwan</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Hong Kong</country>
    <country>Ireland</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Saudi Arabia</country>
    <country>Singapore</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>indolent Non-Hodgkin lymphoma</keyword>
  <keyword>rituximab-refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

